Month: March 2023

LOS ANGELES, CA, March 20, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — On Tuesday, March 14, 2023, the US Environmental Protection Agency (EPA) proposed a first-ever national standard establishing legally enforceable limits for six toxic PFAS forever chemicals. This was welcome news for US Nuclear Corp. (OTC-QB: UCLE) who recently developed and started selling the world’s first real-time PFAS monitor that can measure PFAS contamination in under a minute. Until now, there were only a few states that enforced PFAS regulations, and none as strict as what the EPA is now proposing. Public concern has grown substantially in recent years as new testing revealed the extent and danger of PFAS contamination to all Americans. If the proposal is finalized, businesses and drinking water providers across the country will need to start monitoring...

NEW YORK, March 20, 2023 (GLOBE NEWSWIRE) — SuRo Capital Corp. (“SuRo Capital”, the “Company”, “we”, “us”, and “our”) (Nasdaq: SSSS) announced today that it will commence a modified “Dutch Auction” tender offer (the “Tender Offer”) to purchase up to 3 million shares of its common stock at a price per share not less than $3.00 and not greater than $4.50 in $0.10 increments, using available cash. “As we have consistently demonstrated, SuRo Capital is committed to initiatives that enhance shareholder value, and we believe the market is currently undervaluing our portfolio. Accordingly, on March 17, 2023, our Board of Directors authorized a modified Dutch Auction Tender Offer to purchase up to 3 million shares of our common stock at a price per share between $3.00 and $4.50. Given our stock is trading at a significant discount to net...

— IRAK4 Program Represents the First of Up to Five Degrader Programs Within the 2019 Discovery Collaboration Agreement — — Nurix to Receive a $20 Million Option Fee — FOSTER CITY, Calif. and SAN FRANCISCO, March 20, 2023 (GLOBE NEWSWIRE) — Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies, today announced that Gilead has exercised its option to exclusively license Nurix’s investigational targeted protein degrader molecule NX-0479. This bivalent degrader, designated GS-6791, is the first development candidate resulting from the previously announced Nurix-Gilead collaboration to discover, develop, and commercialize a pipeline of innovative targeted protein degradation therapies. GS-6791...

The next iteration of HOLO Portal delivers advancements based on early clinical experience and insights from leading spine surgeons in the U.S. DEERFIELD, Ill., March 20, 2023 (GLOBE NEWSWIRE) — Surgalign Holdings, Inc. (Nasdaq: SRGA), a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today announced the first major upgrade of the HOLO Portal™ Surgical Guidance System since the first case was performed in May of 2022. Since launch, the Company has worked with surgeons to enhance system functionality and expand use cases in the operating room. This next generation system from Surgalign includes over 250 enhancements in software, hardware upgrades, and integration with new instrumentation, including over 20 new surgical tools designed for use with HOLO...

Special meeting of stockholders to approve proposed business combination with Zapp Electric Vehicles Limited to be held on April 12, 2023 Record date for special meeting is February 13, 2023 Upon closing, Zapp Electric Vehicles Group Limited ordinary shares and warrants will be listed on Nasdaq under the new ticker symbols “ZAPP” and “ZAPPW”NEW YORK and LONDON, March 20, 2023 (GLOBE NEWSWIRE) — CIIG Capital Partners II, Inc. (Nasdaq: CIIG) (“CIIG II”) today announced that the U.S. Securities and Exchange Commission (“SEC”) has declared effective the registration statement on Form F-4 (File No. 333-268857) (as amended, the “Registration Statement”) of Zapp Electric Vehicles Group Limited (“Pubco”), which includes a definitive proxy statement/prospectus in connection with CIIG II’s special meeting of stockholders (the “Special...

TORONTO, March 20, 2023 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties in patients with mild to moderate COVID-19. On March 8th, 2023, the Company announced that it had received the Type C meeting written responses from the FDA to obtain agreement on the proposed protocol endpoints for the Company’s Study. The FDA recommended that the Company’s proposed primary symptom-based endpoint should...

MESA, Ariz., March 20, 2023 (GLOBE NEWSWIRE) — Atlis Motor Vehicles (Nasdaq: AMV), a vertically integrated electric vehicle technology ecosystem company, and US-owned and operated battery cell manufacturer, will host an Investor Town Hall today, Monday, March 20, 2023, at 7:30pm ET / 4:30pm PT. Executives will share key updates regarding the Company’s latest 10-K filing, battery cell mass production trial progress, insight into growing customer demand, and more. Speakers to include:Mark Hanchett, Chief Executive Officer Annie Pratt, President Apoorv Dwivedi, Chief Financial Officer Kate Sieker, Vice President of People David Apps, Vice President, OperationsTo receive a link to the presentation, please sign up here: https://bit.ly/AMVtownhall. About Atlis Motor Vehicles Atlis Motor Vehicles is a technology company driving cutting-edge...

ST. LOUIS, March 20, 2023 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the grand opening of a new robotic electrophysiology program at Broward Health Medical Center in Fort Lauderdale, Florida. Broward Health is among the first in the nation, and the first in Florida, to offer the latest Genesis Robotic Magnetic Navigation System to treat heart rhythm disorders. “Advancing patient care is our number one priority, and we are excited to make this unique technology available, expanding our electrophysiology capabilities to treat the most complex heart arrhythmias with heightened precision,” said Ahmed Osman, M.D., Medical Director of Cardiac Electrophysiology. The Genesis RMN system introduces the benefits of robotic precision...

  Monday, March 20, 2023   Dear Shareholders and Investors, There is nervousness in the stock markets. This nervousness does not impact Nordic American Tankers Ltd (NAT). We would like to highlight three observations on the market for oil transportation: Firstly:             We are not affected by the banking crisis that we see. Secondly:        We are not affected by the fluctuations in the oil price. Thirdly:            The market for our vessels continue to be strong  When we experienced uncertainty in the banking world in 2008, the order book for new suezmax tankers the following months and years stood at about 50% of the existing fleet. At this time, the corresponding number is at a low level of 2%, the lowest we have seen for decades. The supply side of our market is protected for years to come, thereby strengthening the fundamentals....